Failed deal, bidding war paved the way for Ipsen's $952M rare disease buyout
Ipsen may have a mysterious company to thank for its $952 million takeover of Albireo Pharma.
While the French pharma ultimately elbowed two potential buyers to win over Albireo, negotiating down to the final rounds, it was an unnamed “Company A” that kicked off the M&A action, a new SEC filing revealed. In fact, Albireo, which markets Bylvay to treat a severe liver disease, managed to get Company A to up its offer again and again — before it walked away.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.